This suggests that dynamic [18F]florbetapir and [18F]flortaucipir PET scans do not only provide quantitative information of amyloid-β and tau pathology but also yield estimates on rCBF and ultimately circumvent the need for an additional [15O]H2O, [18F]FDG scan or MRI for AD patients. This evidence concerns the gene MAPT and Alzheimer disease.